Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al
Omvoh hit both primary and key secondary endpoints in its pivotal trials, including sustained clinical remission, and Lilly noted that the drug delivered significant improvement in bowel urgency, which patients reported as one of the most disruptive symptoms of UC
Pay close attention to how your body responds and adjust your lifestyle habits to complement your medication regimen
Retatrutide extends further as a triple agonist across GIP, GLP-1, and glucagon (GCGR) receptors
Tapering is often recommended to help your body ease off the medication and reduce the risk of rapid appetite return